Medication side effects and retention in HIV treatment: A regression discontinuity study of tenofovir implementation in South Africa and Zambia

American Journal of Epidemiology

Volumn 187, Issue 9, 2018, Pages 1990-2001

  Brennan, Alana T ^a,b   Bor, Jacob ^a,b   Davies, Mary Ann ^c   Wandeler, Gilles ^e,f   Prozesky, Hans ^g   Fatti, Geoffrey ^h   Wood, Robin ^c   Stinson, Kathryn ^c   Tanser, Frank ^i,j,k   Bärnighausen, Till ^i,l,m   Boulle, Andrew ^c,d   Sikazwe, Izukanji ⁿ   Zanolini, Arianna ⁿ   Fox, Matthew P ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d WESTERN CAPE DEPARTMENT OF AGRICULTURE   (South Africa)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h Kheth'Impilo AIDS free living   (South Africa)

ⁱ AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^j UNIVERSITY OF KWAZULU NATAL   (South Africa)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

more..

Author keywords

Africa; Antiretroviral therapy; Human immunodeficiency virus; Low and middle income countries; Regression discontinuity; Stavudine; Tenofovir; Treatment outcomes

Indexed keywords

TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CONFIDENCE INTERVAL; DEVELOPING WORLD; DISEASE TREATMENT; DRUG; GUIDELINE; HEALTH CARE; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; INHIBITOR; POLICY IMPLEMENTATION; REGRESSION ANALYSIS;

ADULT; ADVERSE OUTCOME; ARTICLE; COHORT ANALYSIS; DISEASE CONTROL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; THERAPY DELAY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ZAMBIA; EPIDEMIOLOGY; IMMUNOLOGY; MEDICATION COMPLIANCE; MORTALITY; VALIDATION STUDY; VIRUS LOAD;

SOUTH AFRICA; ZAMBIA;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; ANTI-HIV AGENTS; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; SOUTH AFRICA; TENOFOVIR; VIRAL LOAD; ZAMBIA;

EID: 85050554254     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwy093     Document Type: Article

References (65)

1. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 345:e4348.
2. Tufts Center for the Study of Drug Development. Briefing: Cost of Developing a New Drug. November 18, 2014. Boston, MA: Tufts University; 2014. https://www. scribd. com/ document/330419323/Tufts-CSDD-Briefing-on-RD-Cost-Study-Nov-18-2014. Accessed September 1, 2017.
3. Food and Drug Administration, US Department of Health and Human Services. Drug Approval Process. Silver Spring, MD: US Food and Drug Administration; http://www. fda. gov/ downloads/Drugs/ResourcesForYou/Consumers/ UCM284393. pdf. Accessed September 1, 2017.
4. Pharmaceutical Research and Manufacturers of America. Medicines in Development for HIV 2017 Report. More Than 50 Medicines and Vaccines in Development for HIV/AIDS Infection Treatment and Prevention. Washington, DC: Pharmaceutical Research and Manufacturers of America; 2017. http://www. phrma. org/report/medicines-indevelopment-for-hiv-2017-report. Accessed September 1, 2017.
5. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2013. http:// www. who. int/hiv/pub/guidelines/arv2013/en/. Accessed October 29, 2017.
6. Uzochukwu BS, Onwujekwe OE, Onoka AC, et al. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan. 2009;24(3): 189-196.
7. Monjok E, Smesny A, Okokon IB, et al. Adherence to antiretroviral therapy in Nigeria: an overview of research studies and implications for policy and practice. HIV AIDS (Auckl). 2010;2:69-76.
8. La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV. 2016;3(6):e247-e258.
9. Paton NI, Stöhr W, Arenas-Pinto A, et al. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. Lancet HIV. 2015;2(10):e417-e426.
10. Raffi F, Babiker AG, Richert L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised noninferiority trial. Lancet. 2014;384(9958):1942-1951.
11. Wohl DA, Bhatti L, Small CB, et al. Simplification to abacavir/ lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One. 2014; 9(5):e96187.
12. PLoS One. 2014;9(7):e103925
13. Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/ tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(3):81-91.
14. Squires KE, Young B, DeJesus E, et al. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2012;13(5):233-244.
15. Gilks CF, Walker AS, Dunn DT, et al. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther. 2012;17(7):1363-1373.
16. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191-201.
17. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47(1):74-78.
18. Velen K, Lewis JJ, Charalambous S, et al. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One. 2013;8(5):e64459.
19. Bygrave H, Ford N, van Cutsem G, et al. Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. J Acquir Immune Defic Syndr. 2011;56(3):e75-e78.
20. Chi BH, Mwango A, GigantiM, et al. Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr. 2010;54(1): 63-70.
21. Njuguna C, Orrell C, Kaplan R, et al. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS One. 2013; 8(5):e63596.
22. Inzaule S, Otieno J, Kalyango J, et al. Incidence and predictors of first line antiretroviral regimen modification in western Kenya. PLoS One. 2014;9(4):e93106.
23. Labhardt ND, Sello M, Lejone T, et al. Adoption of new HIV treatment guidelines and drug substitutions within first-line as a measure of quality of care in rural Lesotho: health centers and hospitals compared. Trop Med Int Health. 2012;17(10): 1245-1254.
24. Brennan AT, Shearer K, Maskew M, et al. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014;19(5): 490-498.
25. Springer SA, Friedland GH, Doros G, et al. Antiretroviral treatment regimen outcomes among HIV infected prisoners. HIV Clin Trials. 2007;8(4):205-212.
26. Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007; 21(12):1579-1589.
27. Vo TT, Ledergerber B, Keiser O, et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis. 2008; 197(12):1685-1694.
28. Lodwick RK, Smith CJ, Youle M, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS. 2008;22(9):1039-1046.
29. Kumarasamy N, Vallabhaneni S, Cecelia AJ, et al. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. J Acquir Immune Defic Syndr. 2006;41(1):53-58.
30. World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for Public Health Approach. 2003 Revision. Geneva, Switzerland: World Health Organization; 2004. http://www. who. int/hiv/pub/prev- care/en/arvrevision2003en. pdf. Accessed October 29, 2017.
31. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10): 1273-1281.
32. Domingos H, Cunha RV, Paniago AM, et al. Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis. 2009;13(2):130-136.
33. van Griensven J, Zachariah R, Rasschaert F, et al. Stavudineand nevirapine-related drug toxicity while on generic fixeddose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg. 2010;104(2):148-153.
34. Murphy RA, Sunpath H, Kuritzkes DR, et al. Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis. 2007;196(suppl 3):S449-S456.
35. Ait-Mohand H, Bonmarchand M, Guiguet M, et al. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med. 2008;9(9): 738-746.
36. Cournil A, Coudray M, Kouanfack C, et al. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Antivir Ther. 2010;15(7):1039-1043.
37. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Recommendations for a Public Health Approach. 2010 Revision. Geneva, Switzerland: World Health Organization; 2010. http://apps. who. int/iris/ bitstream/10665/44379/1/9789241599764-eng. pdf. Accessed October 29, 2017.
38. Wasti SP, Simkhada P, Randall J, et al. Factors influencing adherence to antiretroviral treatment in Nepal: a mixedmethods study. PLoS One. 2012;7(5):e35547.
39. Brennan AT, Maskew M, Ive P, et al. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013;16:18794.
40. Cheng AK, Chen SS, Wulfsohn M, et al. 2 year long term safety profile of tenofovir DF (TDF) in treatment-experienced patients from randomized, double-blind, placebo-controlled clinical trials [poster 7. 3/7]. Presented at the 9th European AIDS Conference, Warsaw, Poland, October 25-29, 2003. http://archives. who. int/eml/expcom/expcom15/applications/ newmed/tenofovir/Cheng-2003-9thEurAIDSConf- Poster737-EN6137. pdf. Accessed January 1, 2018.
41. Thistlethwaite DL, Campbell DT. Regression-discontinuity analysis: an alternative to the ex-post facto experiment. J Educ Psychol. 1960;51(6):309-317.
42. Imbens GW, Lemieux T. Regression discontinuity designs: a guide to practice. J Econom. 2008;142(2):615-635.
43. Jacobson R, Zhu P, Somers MA, et al. A Practical Guide to Regression Discontinuity. New York, NY: MDRC; 2012. http://www. mdrc. org/sites/default/files/regression- discontinuity-full. pdf. Accessed September 1, 2017.
44. Bor J, Moscoe E, Mutevedzi P, et al. Regression discontinuity designs in epidemiology: causal inference without randomized trials. Epidemiology. 2014;25(5):729-737.
45. Egger M, Ekouevi DK, Williams C, et al. Cohort profile: the International epidemiological Databases to Evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol. 2012;41(5): 1256-1264.
46. National Department of Health, Republic of South Africa. The South African Antiretroviral Treatment Guidelines 2010. Pretoria, South Africa: National Department of Health; 2010. http://apps. who. int/medicinedocs/documents/s19153en/ s19153en. pdf. Accessed October 29, 2017.
47. Ministry of Health, Republic of Zambia. Adult and Adolescent Antiretroviral Therapy Protocols. Lusaka, Zambia: Ministry of Health; 2010. http://www. who. int/hiv/pub/guidelines/zambia- art. pdf. Accessed October 29, 2017.
48. Mwinga A. Inclusion of a tenofovir-based first-line regimen in Zambia: a bold step forward? Presented at the 2007 HIV/ AIDS Implementer'sMeeting, Kigali, Rwanda, June 16-19, 2007.
49. Statistics South Africa. Mortality and Causes of Death in South Africa, 1997-2003. Findings From Death Notification. Pretoria, South Africa: Statistics South Africa; 2005. (Statistical release P0309. 3). https://www. statssa. gov. za/ publications/P03093/P03093. pdf. Accessed October 29, 2017.
50. Timaeus I, Dorrington R, Bradshaw D, et al. Mortality Trends in South Africa 1985-2000: From Apartheid to AIDS. Cape Town, South Africa: South African Medical Research Council; 2002.
51. Moscoe E, Bor J, Bärnighausen T. Regression discontinuity designs are underutilized in medicine, epidemiology, and public health: a review of current and best practice. J Clin Epidemiol. 2015;68(2):122-133.
52. Lee DS, Lemieux T. Regression discontinuity designs in economics. J Econ Lit. 2010;48(2):281-355.
53. O'Keeffe AG, Geneletti S, Baio G, et al. Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data. BMJ. 2014;349:g5293.
54. Bor J, Moscoe E, Bärnighausen T. Three approaches to causal inference in regression discontinuity designs. Epidemiology. 2015;26(2):e28-e30.
55. Bor J, Geldsetzer P, Venkataramani A, et al. Quasiexperiments to establish causal effects of HIV care and treatment and to improve the cascade of care. Curr Opin HIV AIDS. 2015;10(6):495-501.
56. Imbens GW, Kalyanaraman K. Optimal bandwidth choice for the regression discontinuity estimator. Rev Econ Stud. 2011; 79(3):933-959.
57. Imbens GW, Rubin DB. Estimating outcome distributions for compliers in instrumental variables models. Rev Econ Stud. 1997;64(4):555-574.
58. Abadie A. Semiparametric instrumental variables estimation of treatment response models. J Econom. 2003;113(2): 231-263.
59. McCrary J. Manipulation of the running variable in the regression discontinuity design: a density test. J Econom. 2008;142(2):698-714.
60. Rubin DB. Assignment to treatment group on the basis of a covariate. J Educ Behav Stat. 1977;2(1):1-26.
61. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009;4(6):e5790.
62. Coffie PA, Patassi A, Doumbia A, et al. Changes in viral hepatitis B screening practices over time in West African HIV clinics. Med Mal Infect. 2017;47(6):394-400.
63. World Health Organization. Global Update on HIV Treatment 2013: Results, Impact and Opportunities. Geneva, Switzerland: World Health Organization; 2013. http://apps. who. int/iris/bitstream/10665/85326/1/9789241505734-eng. pdf. Accessed October 29, 2017.
64. Bor J, Fox MP, Rosen S, et al. Treatment eligibility and retention in clinical HIV care: a regression discontinuity study in South Africa. PLoS Med. 2017; 14(11):e1002463.
65. Clinton Foundation. Antiretroviral (ARV) Price List. New York, NY: Clinton Foundation; 2009. http://www. givewell. org/files/DWDA%202009/Interventions/WJCF-ARVPrices-2009. pdf. Accessed September 1, 2017.